Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nicardipine Hydrochloride,Superoxide Dismutase,Emu oil
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : H-100 (nicardipine), a novel, patented, non-invasive topical treatment being developed for Peyronie’s disease, is being developed as a topical gel using nanotechnology to potentially enhance permeation of the medication.
Brand Name : H100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 03, 2022
Lead Product(s) : Nicardipine Hydrochloride,Superoxide Dismutase,Emu oil
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Avanafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Endo Pharm
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : STENDRA (avanafil), an oral phosphodiesterase 5 (PDE5) inhibitor for treatment of erectile dysfunction, provides positive results from its OTC draft label comprehension study for its ED drug demonstrated understanding of the messages therein.
Brand Name : Stendra
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2022
Lead Product(s) : Avanafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Endo Pharm
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Avanafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Partnership
Details : The new partnership, which replaces a previous agreement with Vivus, will transfer manufacturing of the STENDRA (avanafil) tablets, to the United States, and is expected to provide both cost savings and increase in gross margin.
Brand Name : Stendra
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 24, 2022
Lead Product(s) : Avanafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Avanafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Katalyst Securities LLC
Deal Size : $10.0 million
Deal Type : Public Offering
Petros Pharmaceuticals Announces Closing of $10 Million Offering
Details : Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of Petros Pharmaceuticals' men's health platform including Stendra and for working capital and general corporate purposes.
Brand Name : Stendra
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 30, 2021
Lead Product(s) : Avanafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Katalyst Securities LLC
Deal Size : $10.0 million
Deal Type : Public Offering
Lead Product(s) : Nicardipine Hydrochloride,Superoxide Dismutase,Emu oil
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Hybrid Medical
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : H-100 may be able to provide the first-ever non-invasive treatment to a confounding and often painful condition for which there have been few viable solutions. As a topical, H-100 has the potential to be approved as the first non-invasive treatment for t...
Brand Name : H100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 08, 2021
Lead Product(s) : Nicardipine Hydrochloride,Superoxide Dismutase,Emu oil
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Hybrid Medical
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Avanafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Hims & Hers Health, Inc.
Deal Size : Undisclosed
Deal Type : Agreement
Details : Further expanding the partnership, the companies announce the availability of additional dosages of STENDRA in 50mg, 100mg and 200mg tablets, all of which are now accessible through the Hims platform.
Brand Name : Stendra
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 03, 2021
Lead Product(s) : Avanafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Hims & Hers Health, Inc.
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Avanafil
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Katalyst Securities
Deal Size : $5.7 million
Deal Type : Public Offering
Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering
Details : Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of its men's health platform which includes enhancing the position of STENDRA, and for working capital and general corporate purposes.
Brand Name : Stendra
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 19, 2021
Lead Product(s) : Avanafil
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Katalyst Securities
Deal Size : $5.7 million
Deal Type : Public Offering
Lead Product(s) : Avanafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Meeting to Petros Pharma Discuss Label Expansion of Drug STENDRA®
Details : Stendra (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction.
Brand Name : Stendra
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 27, 2021
Lead Product(s) : Avanafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Avanafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Company has initiated a Phase 2 study, which is more significant & Label Comprehension Study that will include low health literacy individuals as part of a multi-step process to develop the behavioral study evidence for FDA to evaluate Stendra for po...
Brand Name : Stendra
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 13, 2021
Lead Product(s) : Avanafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?